

as a species in claim 30. For the Examiner's convenience, the name of the compound is shown below.

EXAMPLE 1

N-Ac-Sar-Gly-Lys(Ac)-D-Leu-Thr-Nva-Ile-Arg-Pro-NHEt

30

Applicants reserve the right to file divisional applications on any non-pending or non-elected subject matter.

Applicants apologize for the confusion regarding the restriction response sent on February 12, 2003. Should the Examiner have questions or concerns regarding the foregoing, 35 he is respectfully invited to contact the undersigned by telephone at the phone number provided below.



23492
ABBOTT LABORATORIES
Telephone: (847) 935-7956
Facsimile: (847) 938-2623


Respectfully submitted,
F. Haviv, et al.



Johanna M. Corbin
Registration No. 51,582
Attorney for Applicants

40 Amended Version of Claims:

1 (currently amended). A compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein

45 Xaa_1 is absent or Xaa_1 is selected from the group consisting of hydrogen and an acyl group, wherein the acyl group is selected from the group consisting of $\text{R}^1\text{-(CH}_2\text{n-C(O)-}$, wherein n is an integer from 0 to 8 and R^1 is selected from the group consisting of N-acetyl amino, alkoxy, alkyl, aryl, carboxy, cycloalkenyl, cycloalkyl, heterocycle, hydroxy; and

50 $\text{R}^2\text{-CH}_2\text{CH}_2\text{-O-(CH}_2\text{CH}_2\text{O)}_p\text{-CH}_2\text{-C(O)-}$, wherein p is an integer from 1 to 8 and R^2 is selected from the group consisting of hydrogen, N-acetyl amino, and alkyl;

Xaa_2 is an amino acyl residue selected from the group consisting of alanyl,

55 β -alanyl,
asparaginyl,
citrullyl,
N-ethylglycyl,
glutaminyl,
glutamyl,
methionyl,
N-methylalanyl,
N-methylprolyl,
prolyl,
pyro-glutamyl,
sarcosyl,
seryl,
threonyl,

65 $\text{H}_3\text{C-C(O)-HN-(CH}_2\text{)}_q\text{-C(O)-}$, wherein q is an integer from 1 to 8, and
70 $\text{H}_3\text{C-C(O)-HN-CH}_2\text{CH}_2\text{-O-(CH}_2\text{CH}_2\text{O)}_r\text{-CH}_2\text{-C(O)-}$, wherein r is an integer from 1 to 8;

with the proviso that Xaa_1 is absent when Xaa_2 is N-methylprolyl, $\text{H}_3\text{C-C(O)-HN-(CH}_2\text{)}_q\text{-C(O)-}$, or $\text{H}_3\text{C-C(O)-HN-CH}_2\text{CH}_2\text{-O-(CH}_2\text{CH}_2\text{O)}_r\text{-CH}_2\text{-C(O)-}$;

75 Xaa_3 is an amino acyl residue selected from the group consisting of

alanyl,
asparaginyl,
aspartyl,
glutaminyl,
80 glutamyl,
glycyl,
leucyl,
methionyl,
phenylalanyl,
85 prolyl, and
seryl;

Xaa₄ is an amino acyl residue selected from the group consisting of
alloisoleucyl,
90 allylglycyl,
2-aminobutyryl,
(1R,4S)-1-aminocyclopent-2-ene-4-carbonyl,
aspartyl,
3-(5-bromothien-2-yl)alanyl,
95 3-(3-chlorophenyl)alanyl,
3-(4-chlorophenyl)alanyl,
3-(3-cyanophenyl)alanyl,
cysteinyl(S-ethyl),
cysteinyl(S-methyl),
100 2,4-diaminobutanoyl,
2,3-diaminopropionyl,
3-(3,4-dimethoxyphenyl)alanyl,
3-(3-fluorophenyl)alanyl,
3-(4-fluorophenyl)alanyl,
105 histidyl,
homophenylalanyl,
homoseryl,
lysyl(N-epsilon-acetyl),
methionyl(sulfone),
110 methionyl(sulfoxide),
3-(4-methylphenyl)alanyl,
3-(naphth-1-yl)alanyl,

3-(naphth-2-yl)alanyl,
ornithyl,
115 phenylglycyl,
prolyl,
3-(3-pyridyl)alanyl,
seryl(benzyl),
styrylalanyl,
120 1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
3-(thiazolyl)alanyl,
3-(thien-2-yl)alanyl,
D-3-(thien-2-yl)alanyl,
tryptyl,
125 tyrosyl, and
D-valyl;

Xaa₅ is an amino acyl residue selected from the group consisting of

D-alanyl,
130 alloisoleucyl,
D-alloisoleucyl,
D-allothreonyl,
D-allylglycyl,
D-2-aminobutyryl,
135 D-3-(4-aminophenyl)alanyl,
D-asparaginyl,
D-aspartyl,
D-3-(4,4'-biphenyl)alanyl,
D-*t*-butylglycyl,
140 D-3-(4-chlorophenyl)alanyl,
D-citrullyl,
D-3-(3-cyanophenyl)alanyl,
D-cyclohexylalanyl,
D-cyclohexylglycyl,
145 D-cysteinyl,
D-cysteinyl(S-*t*-butyl),
dehydroleucyl,
D-3-(3,4-difluorophenyl)alanyl,
D-3-(3,4-dimethoxyphenyl)alanyl,

150 D-glutaminyl,
D-glutamyl,
glycyl,
D-histidyl,
D-homoisoleucyl,
155 D-homophenylalanyl,
D-homoseryl,
isoleucyl,
D-isoleucyl,
D-leucyl,
160 D-lysyl,
D-lysyl(N-epsilon-nicotinyl),
D-methionyl,
D-3-(4-methylphenyl)alanyl,
D-3-(naphth-1-yl)alanyl,
165 D-3-(naphth-2-yl)alanyl,
D-neopentylglycyl,
D-3-(4-nitrophenyl)alanyl,
D-norleucyl,
D-norvalyl,
170 D-ornithyl,
D-penicillaminy1,
D-penicillaminy1(S-acetamidomethyl),
D-penicillaminy1(S-benzyl),
D-penicillaminy1(S-methyl),
175 D-phenylalanyl,
prolyl,
D-prolyl,
D-3-(3-pyridyl)alanyl,
D-seryl,
180 D-seryl(O-benzyl),
D-3-(thien-2-yl)alanyl,
D-threonyl,
D-threonyl(O-benzyl),
D-3-(3-trifluoromethylphenyl)alanyl,
185 D-3-(3,4,5-trifluorophenyl)alanyl,
D-tryptyl,

D-tyrosyl(O-benzyl),
D-tyrosyl(O-ethyl),
D-tyrosyl, and
190 D-valyl;

Xaa₆ is an amino acyl residue selected from the group consisting of
alanyl,
allothreonyl,
195 D-allothreonyl,
allylglycyl,
asparaginyl,
cysteinyl,
glutaminyl,
200 glycyl,
histidyl,
homoseryl,
D-homoseryl,
3-(4-hydroxymethylphenyl)alanyl,
205 isoleucyl,
lysyl(N-epsilon-acetyl),
methionyl,
3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
210 norvalyl,
octylglycyl,
ornithyl,
penicillaminyl,
prolyl,
215 3-(3-pyridyl)alanyl,
seryl,
D-seryl,
threonyl,
D-threonyl,
220 tryptyl, and
tyrosyl;

Xaa₇ is an amino acyl residue selected from the group consisting of

225 alanyl,
 allylglycyl,
 2-aminobutyryl,
 arginyl,
 asparaginyl,
 aspartyl,
230 3-(4-carboxyamidophenyl)alanyl,
 citrullyl,
 cyclohexylalanyl,
 cysteinyl,
 glutaminyl,
235 D-glutaminyl,
 glutamyl,
 glycyl,
 histidyl,
 homoalanyl,
240 homoleucyl,
 homoseryl,
 D-homoseryl,
 isoleucyl,
 leucyl,
245 D-leucyl,
 lysyl(N-epsilon-acetyl),
 lysyl(N-epsilon-isopropyl),
 methionyl(sulfone),
 methionyl(sulfoxide),
250 methionyl,
 3-(naphth-1-yl)alanyl,
 D-3-(naphth-1-yl)alanyl,
 3-(naphth-2-yl)alanyl,
 D-3-(naphth-2-yl)alanyl,
255 norleucyl,
 norvalyl,
 D-norvalyl,
 octylglycyl,
 penicillaminyl,
260 phenylalanyl,

- propargylglycyl,
3-(3-pyridyl)alanyl,
seryl,
D-seryl,
265 threonyl,
tryptyl,
tyrosyl, and
valyl;
- Xaa₈ is an amino acyl residue selected from the group consisting of
270 alanyl,
alloisoleucyl,
D-alloisoleucyl,
allylglycyl,
aspartyl,
275 *t*-butylglycyl,
citrullyl,
cyclohexylglycyl,
cysteinyl,
280 glutamyl,
glycyl,
homoseryl,
isoleucyl,
D-isoleucyl,
285 leucyl,
lysyl(N-epsilon-acetyl),
methionyl,
3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
290 norvalyl,
penicillaminyl,
phenylalanyl,
prolyl,
seryl,
tryptyl,
295 tyrosyl, and
valyl;

Xaa₉ is an amino acyl residue selected from

300 [(4-amino(N-isopropyl)methyl)phenyl]alanyl,
 3-(4-amino-N-isopropylphenyl)alanyl,
 arginyl,
 arginyl(N^GN^Gdiethyl),
 citrullyl,
305 3-(cyclohexyl)alanyl(4-N-isopropyl),
 glycyl[4-piperidinyl(N-amidino)],
 (3-guanidino)alanyl,
 3-(4-guanidinophenyl)alanyl,
 histidyl,
310 homoarginyl,
 lysyl,
 lysyl(N-epsilon-isopropyl),
 lysyl(N-epsilon-nicotinyl),
 norarginyl,
315 ornithyl(N-delta-isopropyl),
 ornithyl(N-delta-nicotinyl),
 ornithyl[N-delta-(2-imidazolinyl)],
 [4-piperidinyl(N-amidino)]alanyl, and
 [3-pyrrolidinyl(2-N-amidino)]alanyl;

320

Xaa₁₀ is an amino acyl residue selected from the group consisting of


325 D-alanyl,
 2-aminobutyryl,
 2-aminoisobutyryl,
 t-butylglycyl,
 homoprolyl,
 hydroxyprolyl,
 isoleucyl,
 leucyl,
330 phenylalanyl,
 prolyl,
 D-prolyl,
 seryl,
 1,2,3,4-tetrahydroisoquinoline-3-carbonyl,

335 threonyl, and
valyl;

Xaa₁₁ is a hydroxy group or an amino acid amide selected from the group consisting of

340 D-alanyl amide,
D-alanyl ethyl amide,
azaglycyl amide,
glycyl amide,
glycyl ethyl amide,

345 sarcosyl amide,
seryl amide,
D-seryl amide,
a residue represented by the formula



350 a group represented by the formula -NH-R⁵; wherein
s is an integer selected from 0 to 8;

R³ is selected from the group consisting of hydrogen, alkyl, and a 5-to 6-membered cycloalkyl ring;

R⁴ is selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, cycloalkenyl, cycloalkyl, heterocycle, and hydroxy;

provided that s is not zero when R⁴ is hydroxy or alkoxy; and

R⁵ is selected from hydrogen, hydroxy, and cycloalkyl.

2 (currently amended). A compound according to Claim 1, wherein Xaa₁ is absent or is selected from the group consisting of

hydrogen,
acetyl,
5 N-acetyl-β-alanyl,
(4-N-acetylamino)butyryl,
(6-N-acetylamino)caproyl,
(8-N-acetylamino)-3,6-dioxo-octanoyl,
butyryl,
10 caproyl,
5-chloro-2-hydroxynicotinyl,
5-chloro-6-hydroxynicotinyl,

2-chloroisonicotinyl,
2-chloro-6-methylnicotinyl,
15 cyclohexylacetyl,
furoyl,
2-hydroxy-6-methylnicotinyl,
6-hydroxynicotinyl,
6-hydroxy-2-picolinyl,
20 isonicotinyl,
2-methoxyacetyl,
2-methylnicotinyl,
6-methylnicotinyl,
(4-methyl)phenylacetyl,
25 nicotinyl,
phenylacetyl,
propionyl,
shikimyl,
succinyl, and
30 tetrahydrofuroyl.

3 (original). A compound according to Claim 2 wherein Xaa₁ is selected from the group consisting of
acetyl, and
6-methylnicotinyl.

5 4 (original). A compound according to Claim 1 wherein Xaa₂ is selected from the group consisting of
alanyl,
 β -alanyl,
5 asparaginyl,
citrullyl,
N-ethylglycyl,
glutaminyl,
glutamyl,
10 methionyl,
N-methylalanyl,
N-methylprolyl,
prolyl,

15 pyro-glutamyl,
 sarcosyl,
 seryl,
 threonyl,
 H₃C-C(O)-HN-(CH₂)_q-C(O)-, wherein q is an integer from 1 to 8, and
 H₃C-C(O)-HN-CH₂CH₂-O-(CH₂CH₂O)_r-CH₂-C(O)-, wherein r is an integer from 1
20 to 8.

5 (original). A compound according to Claim 4, wherein Xaa₂ is sarcosyl.

6 (original). The compound according to Claim 1 wherein Xaa₃ is selected from the group consisting of

5 alanyl,
 asparaginyl,
 aspartyl,
 glutaminyl,
 glutamyl,
 glycyl,
 leucyl,
10 methionyl,
 phenylalanyl,
 prolyl, and
 seryl.

7 (original). A compound according to Claim 6 wherein Xaa₃ is glycyl.

8 (original). A compound according to Claim 1 wherein Xaa₄ is selected from the group consisting of

5 alloisoleucyl,
 allylglycyl,
 2-aminobutyryl,
 (1R,4S)-1-aminocyclopent-2-ene-4-carbonyl,
 aspartyl,
 3-(5-bromothien-2-yl)alanyl,
 3-(3-chlorophenyl)alanyl,
10 3-(4-chlorophenyl)alanyl,
 3-(3-cyanophenyl)alanyl,

cysteinyl(S-ethyl),
cysteinyl(S-methyl),
2,4-diaminobutanoyl,
15 2,3-diaminopropionyl,
3-(3,4-dimethoxyphenyl)alanyl,
3-(3-fluorophenyl)alanyl,
3-(4-fluorophenyl)alanyl,
histidyl,
20 homophenylalanyl,
homoseryl,
lysyl(N-epsilon-acetyl),
methionyl(sulfone),
methionyl(sulfoxide),
25 3-(4-methylphenyl)alanyl,
3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
ornithyl,
phenylglycyl,
30 prolyl,
3-(3-pyridyl)alanyl,
seryl(O-benzyl),
styrylalanyl,
1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
35 3-(thiazolyl)alanyl,
3-(thien-2-yl)alanyl,
D-3-(thien-2-yl)alanyl,
tryptyl,
tyrosyl, and
40 D-valyl.

9 (original). A compound according to Claim 8 wherein Xaa₄ is selected from the group consisting of

5 alloisoleucyl,
allylglycyl,
2-aminobutyryl,
(1R,4S)-1-aminocyclopent-2-ene-4-carbonyl,
3-(5-bromothien-2-yl)alanyl,

3-(3-chlorophenyl)alanyl,
3-(4-chlorophenyl)alanyl,
10 3-(3-cyanophenyl)alanyl,
cysteinyl(S-ethyl),
cysteinyl(S-methyl),
2,4-diaminobutanoyl,
2,3-diaminopropionyl,
15 3-(3,4-dimethoxyphenyl)alanyl,
3-(3-fluorophenyl)alanyl,
3-(4-fluorophenyl)alanyl,
histidyl,
homophenylalanyl,
20 homoseryl,
lysyl(N-epsilon-acetyl),
methionyl(sulfone),
methionyl(sulfoxide),
3-(4-methylphenyl)alanyl,
25 3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
ornithyl,
phenylglycyl,
prolyl,
30 3-(3-pyridyl)alanyl,
seryl(O-benzyl),
styrylalanyl,
1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
3-(thiazolyl)alanyl,
35 3-(thien-2-yl)alanyl,
D-3-(thien-2-yl)alanyl,
tryptyl,
tyrosyl, and
D-valyl.

40

10 (original). A compound according to Claim 1, wherein Xaa₅ is selected from the group consisting of

D-alanyl,
alloisoleucyl,

5 D-alloisoleucyl,
D-allothreonyl,
D-allylglycyl,
D-2-aminobutyryl,
D-3-(4-aminophenyl)alanyl,
10 D-asparaginyl,
D-aspartyl,
D-3-(4,4'-biphenyl)alanyl,
D-t-butylglycyl,
D-3-(4-chlorophenyl)alanyl,
15 D-citrullyl,
D-3-(3-cyanophenyl)alanyl,
D-cyclohexylalanyl,
D-cyclohexylglycyl,
D-cysteinyl,
20 D-cysteinyl(S-t-butyl),
dehydroleucyl,
D-3-(3,4-difluorophenyl)alanyl,
D-3-(3,4-dimethoxyphenyl)alanyl,
D-glutaminyl,
25 D-glutamyl,
glycyl,
D-histidyl,
D-homoisoleucyl,
D-homophenylalanyl,
30 D-homoseryl,
isoleucyl,
D-isoleucyl,
D-leucyl,
D-lysyl,
35 D-lysyl(N-epsilon-nicotinyl),
D-methionyl,
D-3-(4-methylphenyl)alanyl,
D-3-(naphth-1-yl)alanyl,
D-3-(naphth-2-yl)alanyl,
40 D-neopentylglycyl,
D-3-(4-nitrophenyl)alanyl,

D-norleucyl,
D-norvalyl,
D-ornithyl,
45 D-penicillaminyl,
D-penicillaminyl(S-acetamidomethyl),
D-penicillaminyl(S-benzyl),
D-penicillaminyl(S-methyl),
D-phenylalanyl,
50 prolyl,
D-prolyl,
D-3-(3-pyridyl)alanyl,
D-seryl,
D-seryl(O-benzyl),
55 D-3-(thien-2-yl)alanyl,
D-threonyl,
D-threonyl(O-benzyl),
D-3-(3-trifluoromethylphenyl)alanyl,
D-3-(3,4,5-trifluorophenyl)alanyl,
60 D-tryptyl,
D-tyrosyl(O-benzyl),
D-tyrosyl(O-ethyl),
D-tyrosyl, and
D-valyl.

65

11 (original). A compound according to Claim 10 wherein Xaa₅ is selected from the group consisting of

5 isoleucyl,
D-isoleucyl, and
D-leucyl.

12 (original). A compound according to Claim 1 wherein Xaa₆ is selected from the group consisting of

5 alanyl,
allothreonyl,
D-allothreonyl,
allylglycyl,
asparaginyl,

cysteinyl,
glutaminyl,
10 glycyl,
histidyl,
homoseryl,
D-homoseryl,
3-(4-hydroxymethylphenyl)alanyl,
15 isoleucyl,
lysyl(N-epsilon-acetyl),
methionyl,
3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
20 norvalyl,
octylglycyl,
ornithyl,
penicillaminyl,
prolyl,
25 3-(3-pyridyl)alanyl,
seryl,
D-seryl,
threonyl,
D-threonyl,
30 tryptyl, and
tyrosyl.

13 (original). A compound according to Claim 12 wherein Xaa₆ is selected from the group consisting of

seryl, and
threonyl.

5

14 (original). A compound according to Claim 1 wherein Xaa₇ is selected from the group consisting of

5 alanyl,
allylglycyl,
2-aminobutyryl,
arginyl,
asparaginyl,

aspartyl,
3-(4-carboxyamidophenyl)alanyl,
10 citrullyl,
cyclohexylalanyl,
cysteinyl,
glutaminyl,
D-glutaminyl,
15 glutamyl,
glycyl,
histidyl,
homoalanyl,
homoleucyl,
20 homoseryl,
D-homoseryl,
isoleucyl,
leucyl,
D-leucyl,
25 lysyl(N-epsilon-acetyl),
lysyl(N-epsilon-isopropyl),
methionyl(sulfone),
methionyl(sulfoxide),
methionyl,
30 3-(naphth-1-yl)alanyl,
D-3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
D-3-(naphth-2-yl)alanyl,
norleucyl,
35 norvalyl,
D-norvalyl,
octylglycyl,
penicillaminyl,
phenylalanyl,
40 propargylglycyl,
3-(3-pyridyl)alanyl,
seryl,
D-seryl,
threonyl,

45 tryptyl,
tyrosyl, and
valyl.

15 (original). A compound according to Claim 14 wherein Xaa₇ is selected from the group consisting of

glutaminyl,
norvalyl, and
5 seryl.

16 (original). A compound according to Claim 1 wherein Xaa₈ is selected from the group consisting of

alanyl,
alloisoleucyl,
5 D-alloisoleucyl,
allylglycyl,
aspartyl,
t-butylglycyl,
citrullyl,
10 cyclohexylglycyl,
cysteinyl,
glutamyl,
glycyl,
homoseryl,
15 isoleucyl,
D-isoleucyl,
leucyl,
lysyl(N-epsilon-acetyl),
methionyl,
20 3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
norvalyl,
penicillaminyl,
phenylalanyl,
25 proyl,
seryl,
tryptyl,

tyrosyl, and
valyl.

30

17 (original). A compound according to Claim 16 wherein Xaa₈ is isoleucyl.

18 (original). A compound according to Claim 1 wherein Xaa₉ is selected from the group consisting of

- [(4-amino(N-isopropyl)methyl)phenyl]alanyl,
3-(4-amino-N-isopropylphenyl)alanyl,
5 arginyl,
arginyl(N^GN^Gdiethyl),
citrullyl,
3-(cyclohexyl)alanyl(4-N-isopropyl),
glycyl[4-piperidinyl(N-amidino)],
10 (3-guanidino)alanyl,
3-(4-guanidinophenyl)alanyl,
histidyl,
homoarginyl,
lysyl,
15 lysyl(N-epsilon-isopropyl),
lysyl(N-epsilon-nicotinyl),
norarginyl,
ornithyl(N-delta-isopropyl),
ornithyl(N-delta-nicotinyl),
20 ornithyl[N-delta-(2-imidazolinyl)],
[4-piperidinyl(N-amidino)]alanyl, and
[3-pyrrolidinyl(2-N-amidino)]alanyl.

19 (original). A compound according to Claim 18 wherein Xaa₉ is arginyl.

20 (original). A compound according to Claim 1 wherein Xaa₁₀ is selected from the group consisting of

- D-alanyl,
2-aminobutyryl,
5 2-aminoisobutyryl,
t-butylglycyl,
homoprolyl,

hydroxyproyl,
isoleucyl,
10 leucyl,
phenylalanyl,
prolyl,
D-prolyl,
seryl,
15 1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
threonyl, and
valyl.

21 (original). A compound according to Claim 20 wherein Xaa₁₀ is prolyl.

22 (original). A compound according to Claim 1 wherein Xaa₁₁ is selected from the group consisting of

D-alanylamide,
D-alanylethylamide,
5 azaglycylamide,
NH-cyclobutyl,
NH-cycloheptyl,
NH-1-(cyclohexyl)ethyl,
NH-2-(cyclohexyl)ethyl,
10 NH-2-(ethoxy)ethyl,
NH-ethyl,
glycylamide,
glycylethylamide,
NH-hexyl,
15 NH-2-(hydroxy)ethyl,
NH-isoamyl,
NH-isobutyl,
NH-2-(isopropoxy)ethyl,
NH-isopropyl,
20 NH-2-(methoxy)ethyl,
NH-3-(methoxy)propyl,
NH-propyl,
NH-2-(1-pyrrolidine)ethyl,
sarcosylamide,

25 serylamide, and
D-serylamide.

23 (original). A compound according to Claim 22 wherein Xaa₁₁ is selected from the group consisting of

D-alanyl amide, and
NH-ethyl.

5

24 (original). A compound according to Claim 1 wherein

Xaa₁ is selected from the group consisting of
acetyl, and
5 6-methylnicotinyl;

Xaa₂ is sarcosyl;

Xaa₃ is glycyl;

10 Xaa₄ is selected from the group consisting of
alloisoleucyl,
allylglycyl,
2-aminobutyryl,
15 (1R,4S)-1-aminocyclopent-2-ene-4-carbonyl,
3-(5-bromothien-2-yl)alanyl,
3-(3-chlorophenyl)alanyl,
3-(4-chlorophenyl)alanyl,
3-(3-cyanophenyl)alanyl,

20 cysteinyl(S-ethyl),
cysteinyl(S-methyl),
2,3-diaminopropionyl,
2,4-diaminobutanoyl,
3-(3,4-dimethoxyphenyl)alanyl,
25 3-(3-fluorophenyl)alanyl,
3-(4-fluorophenyl)alanyl,
histidyl,
homophenylalanyl,
homoseryl,

- 30 lysyl(N-epsilon-acetyl),
 methionyl(sulfone),
 methionyl(sulfoxide),
 3-(4-methylphenyl)alanyl,
 3-(naphth-1-yl)alanyl,
35 3-(naphth-2-yl)alanyl,
 ornithyl,
 phenylglycyl,
 prolyl,
 3-(3-pyridyl)alanyl,
40 seryl(O-benzyl),
 styrylalanyl,
 1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
 3-(thiazolyl)alanyl,
 3-(thien-2-yl)alanyl,
45 D-3-(thien-2-yl)alanyl,
 tryptyl,
 tyrosyl, and
 D-valyl,
- 50 Xaa₅ is selected from the group consisting of
 isoleucyl,
 D-isoleucyl, and
 D-leucyl;
- 55 Xaa₆ is selected from the group consisting of
 seryl, and
 threonyl;
- 60 Xaa₇ is selected from the group consisting of
 glutamyl,
 norvalyl, and
 seryl;
- 65 Xaa₈ is isoleucyl;
 Xaa₉ is arginyl;

Xaa₁₀ is prolyl; and

70 Xaa₁₁ is selected from the group consisting of
D-alanyl amide, and
NH-ethyl.

25 (original). A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

26 (canceled). A method of treating a patient in need of anti-angiogenesis therapy comprising administering to the patient in need a therapeutically effective amount of a compound of Claim 1.

27 (original). A composition for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention, macular degeneration and diabetic retinopathy comprising a compound of Claim 1 in combination with a pharmaceutically acceptable carrier.

5

28 (canceled). A method of isolating a receptor from an endothelial cell comprising binding a compound of Claim 1 to the receptor to form a peptide receptor complex; isolating the peptide receptor complex; and purifying the receptor.

29 (original). A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of

N-Ac-Sar-Gly-5-BrThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-2-Nal-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

5 N-Ac-Sar-Gly-Orn-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-4-ClPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-HPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-Cys(Me)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-Cys(Et)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl, and

10 N-Ac-Sar-Gly-Tyr-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl.

30 (original). A compound, or a therapeutically acceptable salt thereof, selected from the group consisting of

N-Ac-Sar-Gly-Lys(Ac)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

- N-Ac-Sar-Gly-Pro-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
5 N-Ac-Sar-Gly-3-CNPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-Cys(Et)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-4-ThzAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-3,4-diOMePheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
10 N-Ac-Sar-Gly-4-MePheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-3-ClPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-2-ThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-PheGly-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-2,4-Diabu-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
15 N-Ac-Sar-Gly-Met(O₂)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-1-Nal-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-2-Abu-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-Met(O)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-His-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
20 N-Ac-Sar-Gly-Trp-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-Tic-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-StyAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-AllylGly-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-4-FPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
25 N-Ac-Sar-Gly-2,3-Diapr-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-Met(O₂)-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl
N-Ac-Sar-Gly-3-PyrAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-4-ClPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-1-Nal-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl
30 N-Ac-Sar-Gly-2-Nal-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-3-FPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-HPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-4-FPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-alloIle-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
35 N-Ac-Sar-Gly-Ser(Bzl)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-HSer-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Ser-Ser-Ile-Arg-ProNH-ethyl,
N-6MeNic-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-2-ThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
40 N-Ac-Sar-Gly-3-CNPhe-D-Leu-Thr-Nva-Ile-Arg-Pro-D-AlaNH₂,

N-Ac-Sar-Gly-D-Val-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-D-2-ThiAla-D-Leu-Thr-Nva-Ile-Arg-Pro-D-AlaNH₂,
N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Gln-Ile-Arg-ProNH-ethyl, and
N-Ac-Sar-Gly-D-Val-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl.